EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 89 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Three Women Running the Length of Michigan to Raise Funds for... February 4, 2022 EMA Recommends Extension of Indications for Tafasitamab December 4, 2025 ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Load more HOT NEWS FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... Foster Teen With A Passion For Painting Is Patiently Waiting For... Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That...
